3 results on '"LaFontaine, Marisa"'
Search Results
2. Association of Maximal Extent of Resection of Contrast-Enhanced and Non–Contrast-Enhanced Tumor With Survival Within Molecular Subgroups of Patients With Newly Diagnosed Glioblastoma
- Author
-
Molinaro, Annette M., Hervey-Jumper, Shawn, Morshed, Ramin A., Young, Jacob, Han, Seunggu J., Chunduru, Pranathi, Zhang, Yalan, Phillips, Joanna J., Shai, Anny, Lafontaine, Marisa, Crane, Jason, Chandra, Ankush, Flanigan, Patrick, Jahangiri, Arman, Cioffi, Gino, Ostrom, Quinn, Anderson, John E., Badve, Chaitra, Barnholtz-Sloan, Jill, Sloan, Andrew E., Erickson, Bradley J., Decker, Paul A., Kosel, Matthew L., LaChance, Daniel, Eckel-Passow, Jeanette, Jenkins, Robert, Villanueva-Meyer, Javier, Rice, Terri, Wrensch, Margaret, Wiencke, John K., Oberheim Bush, Nancy Ann, Taylor, Jennie, Butowski, Nicholas, Prados, Michael, Clarke, Jennifer, Chang, Susan, Chang, Edward, Aghi, Manish, Theodosopoulos, Philip, McDermott, Michael, and Berger, Mitchel S.
- Abstract
IMPORTANCE: Per the World Health Organization 2016 integrative classification, newly diagnosed glioblastomas are separated into isocitrate dehydrogenase gene 1 or 2 (IDH)–wild-type and IDH-mutant subtypes, with median patient survival of 1.2 and 3.6 years, respectively. Although maximal resection of contrast-enhanced (CE) tumor is associated with longer survival, the prognostic importance of maximal resection within molecular subgroups and the potential importance of resection of non–contrast-enhanced (NCE) disease is poorly understood. OBJECTIVE: To assess the association of resection of CE and NCE tumors in conjunction with molecular and clinical information to develop a new road map for cytoreductive surgery. DESIGN, SETTING, AND PARTICIPANTS: This retrospective, multicenter cohort study included a development cohort from the University of California, San Francisco (761 patients diagnosed from January 1, 1997, through December 31, 2017, with 9.6 years of follow-up) and validation cohorts from the Mayo Clinic (107 patients diagnosed from January 1, 2004, through December 31, 2014, with 5.7 years of follow-up) and the Ohio Brain Tumor Study (99 patients with data collected from January 1, 2008, through December 31, 2011, with a median follow-up of 10.9 months). Image accessors were blinded to patient groupings. Eligible patients underwent surgical resection for newly diagnosed glioblastoma and had available survival, molecular, and clinical data and preoperative and postoperative magnetic resonance images. Data were analyzed from November 15, 2018, to March 15, 2019. MAIN OUTCOMES AND MEASURES: Overall survival. RESULTS: Among the 761 patients included in the development cohort (468 [61.5%] men; median age, 60 [interquartile range, 51.6-67.7] years), younger patients with IDH–wild-type tumors and aggressive resection of CE and NCE tumors had survival similar to that of patients with IDH-mutant tumors (median overall survival [OS], 37.3 [95% CI, 31.6-70.7] months). Younger patients with IDH–wild-type tumors and reduction of CE tumor but residual NCE tumors fared worse (median OS, 16.5 [95% CI, 14.7-18.3] months). Older patients with IDH–wild-type tumors benefited from reduction of CE tumor (median OS, 12.4 [95% CI, 11.4-14.0] months). The results were validated in the 2 external cohorts. The association between aggressive CE and NCE in patients with IDH–wild-type tumors was not attenuated by the methylation status of the promoter region of the DNA repair enzyme O6-methylguanine-DNA methyltransferase. CONCLUSIONS AND RELEVANCE: This study confirms an association between maximal resection of CE tumor and OS in patients with glioblastoma across all subgroups. In addition, maximal resection of NCE tumor was associated with longer OS in younger patients, regardless of IDH status, and among patients with IDH–wild-type glioblastoma regardless of the methylation status of the promoter region of the DNA repair enzyme O6-methylguanine-DNA methyltransferase. These conclusions may help reassess surgical strategies for individual patients with newly diagnosed glioblastoma.
- Published
- 2020
- Full Text
- View/download PDF
3. Quantitative assessment of preanalytic variables on clinical evaluation of PI3/AKT/mTOR signaling activity in diffuse glioma
- Author
-
Beccari, Sol, Mohamed, Esraa, Voong, Viva, Hilz, Stephanie, Lafontaine, Marisa, Shai, Anny, Lim, Yunita, Martinez, Jerry, Switzman, Benjamin, Yu, Ryon L., Lupo, Janine M., Chang, Eddie F., Hervey-Jumper, Shawn L., Berger, Mitchel S., Costello, Joseph F., and Phillips, Joanna J.
- Abstract
Biomarker-driven therapeutic clinical trials require implementation of standardized, evidence-based practices for sample collection. In diffuse glioma, phosphatidylinositol 3 (PI3)-kinase/AKT/mTOR (PI3/AKT/mTOR) signaling is an attractive therapeutic target for which window of opportunity clinical trials could facilitate identification of promising new agents. Yet, the relevant preanalytic variables and optimal tumor sampling methods necessary to measure pathway activity are unknown. To address this, we used a murine model for IDH-wildtype glioblastoma (GBM) and human tumor tissue, including IDH-wildtype GBM and IDH-mutant diffuse glioma. First, we determined the impact of delayed time-to-formalin fixation, or cold ischemia time (CIT), on the quantitative assessment of cellular expression of six phosphoproteins that are readouts of PI3K/AK/mTOR activity (phosphorylated -proline-rich Akt substrate of 40 kDa (p-PRAS40, T246), -mechanistic target of rapamycin (p-mTOR; S2448); -AKT (p-AKT, S473); -ribosomal protein S6 (p-RPS6, S240/244 and S235/236), and -eukaryotic initiation factor 4E–binding protein 1 (p-4EBP1, T37/46). With CITs ≥2 hours, typical of routine clinical handling, all had reduced or altered expression with p-RPS6 (S240/244) exhibiting relatively greater stability. A similar pattern was observed using patient tumor samples from the operating room with p-4EBP1 more sensitive to delayed fixation than p-RPS6 (S240/244). Many clinical trials utilize unstained slides for biomarker evaluation. Thus, we evaluated the impact of slide storage conditions on the detection of p-RPS6 (S240/244), p-4EBP1, and p-AKT. After 5 months, storage at -80ºC was required to preserve the expression of p-4EBP1 and p-AKT while p-RPS6 (240/244) expression was not stable regardless of storage temperature. Biomarker heterogeneity impacts optimal tumor sampling. Quantification of p-RPS6 (240/244) expression in multiple regionally distinct human tumor samples from eight patients revealed significant intratumoral heterogeneity. Thus, the accurate assessment of PI3K/AKT/mTOR signaling in diffuse glioma must overcome intratumoral heterogeneity and multiple preanalytic factors, including time-to-formalin fixation, slide storage conditions, and phosphoprotein of interest.
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.